MAIA生物技术股份有限公司美股招股说明书（2026年3月2日版）

The information in this prospectus is not complete and may be changed. We may not sell these securities or accept an offer tobuy these securities until the registration statement filed with the U.S. Securities and Exchange Commission is effective. Thisprospectus is not an offer to sell these securities, and we are not soliciting an offer to buy these securities in any state where the SUBJECT TO COMPLETION, DATED MARCH 2, 2026 PRELIMINARY PROSPECTUS SUPPLEMENT(To Prospectus dated August 23, 2023) Up toShares of Common StockUp toPre-Funded Warrants to Purchase Shares of Common Stock shares of our common stock, $0.0001 par value per share. We are offering up to We are also offering to each purchaser whose purchase of shares of our common stock in this offering would otherwise resultin the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of thepurchaser, 9.99%) of the outstanding shares of common stock immediately following the consummation of this offering, theopportunity to purchase, if the purchaser so chooses, pre-funded warrants to purchase shares of common stock, or the pre-fundedwarrants, in lieu of shares of common stock. Each pre-funded warrant will be exercisable for one share of our common stock and willbe immediately exercisable and will expire when exercised in full. The purchase price of each pre-funded warrant and accompanying Our common stock is listed on the NYSE American (“NYSE”) under the symbol “MAIA.” There is no established publictrading market for the pre-funded warrants, and we do not expect a market to develop. We have not applied, and do not intend to apply,to list the pre-funded warrants on the NYSE. On February 27, 2026, the last reported sale price of our common stock on the NYSE Investing in our securities involves a high degree of risk. You should read the “Risk Factors’’ section beginning onpage S-14 of this prospectus supplement and page 9 of the accompanying prospectus and in the documents incorporated by (1)5% cash fee payable to the underwriters and to and to reimburse the underwriters for certain offering-related expenses. See“Underwriting” beginning on page S-20 of this prospectus supplement for additional information regarding underwriting We have granted the underwriters a 30-day option to purchase up toadditional shares of common stock and/or pre-funded warrants from us at the same terms and conditions set forth above. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved ofthese securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any Book-Running ManagersKonik Capital Partnersa division of T.R. Winston & Co. Table of Contents ABOUT THIS PROSPECTUS SUPPLEMENT This prospectus supplement and the accompanying prospectus are part of a registration statement on Form S-3 (File No. 333-273984) we filed with the Securities and Exchange Commission, or SEC, on August 23, 2023, and that was declared effective by theSEC on December 18, 2024, using a “shelf” registration process. This document is in two parts. The first part is this prospectussupplement, which describes the specific terms of this offering of common stock and pre-funded warrants and also adds to and updatesinformation contained in the accompanying prospectus and the documents incorporated by reference herein. The second part, theaccompanying prospectus, including the documents incorporated by reference therein, provides more general information, some ofwhich may not apply to this offering. Generally, when we refer to this prospectus, we are referring to both parts of this document We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit toany document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, insome cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, You should rely only on the information contained in this prospectus supplement or the accompanying prospectus orincorporated by reference herein. We have not authorized, and the underwriters have not authorized, anyone to provide you withinformation that is different. The information contained in this prospectus supplement or the accompanying prospectus or incorporated This prospectus supplement and the accompanying prospectus contain summaries of certain provisions contained in some ofthe documents described herein, but reference is made to the actual documents for complete information. All of the summaries arequalified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or It is important for you to read and consider all information contained in this prospectus supplement a